Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
Type:
Application
Filed:
March 13, 2014
Publication date:
October 9, 2014
Applicants:
The Government of the United States of America as Represented by the Secretar, INVIRAGEN, INC.
Inventors:
Daniel T. Stinchcomb, Claire Y Huang, Richard M Kinney, Jill A Livengood
Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
Type:
Application
Filed:
March 13, 2014
Publication date:
September 18, 2014
Applicant:
INVIRAGEN, INC.
Inventors:
Daniel T. Stinchcomb, Jill A. Livengood, Lazlo Varga
Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
Type:
Application
Filed:
November 8, 2013
Publication date:
May 15, 2014
Applicants:
The Government of the United States of America as Represented by the Secretary of Health & Human S, INVIRAGEN, INC.
Inventors:
Jill A. Livengood, Claire Y. Huang, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.
Type:
Application
Filed:
November 24, 2010
Publication date:
February 7, 2013
Applicant:
INVIRAGEN, INC.
Inventors:
Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Joseph N. Brewoo
Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
Type:
Grant
Filed:
April 4, 2008
Date of Patent:
December 27, 2011
Assignee:
Inviragen, Inc.
Inventors:
Dan T. Stinchcomb, Jorge E. Osorio, O'Neil Wiggan